KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Free Cash Flow (2018 - 2025)

Adaptive Biotechnologies' Free Cash Flow history spans 8 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 108.8% year-over-year to $1.4 million; the TTM value through Dec 2025 reached -$48.9 million, up 50.5%, while the annual FY2025 figure was -$48.9 million, 50.5% up from the prior year.
  • Free Cash Flow for Q4 2025 was $1.4 million at Adaptive Biotechnologies, up from -$7.5 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $1.4 million in Q4 2025 and bottomed at -$88.9 million in Q3 2021.
  • The 5-year median for Free Cash Flow is -$33.2 million (2021), against an average of -$37.2 million.
  • The largest annual shift saw Free Cash Flow plummeted 104.58% in 2021 before it skyrocketed 108.8% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$63.1 million in 2021, then skyrocketed by 71.57% to -$17.9 million in 2022, then dropped by 1.61% to -$18.2 million in 2023, then grew by 11.49% to -$16.1 million in 2024, then surged by 108.8% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Free Cash Flow are $1.4 million (Q4 2025), -$7.5 million (Q3 2025), and -$13.1 million (Q2 2025).